Denis Chem Lab (DENISCHEM) | Financial Analysis & Statements
Denis Chem Lab Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
432.8M
Gross Profit
187.1M
43.24%
Operating Income
32.0M
7.40%
Net Income
24.8M
5.72%
EPS (Diluted)
₹1.78
Balance Sheet Metrics
Total Assets
1.1B
Total Liabilities
271.7M
Shareholders Equity
851.0M
Debt to Equity
0.32
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Denis Chem Lab Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.7B | 1.7B | 1.6B | 1.4B | 1.1B |
| Cost of Goods Sold | 981.9M | 868.6M | 844.6M | 742.2M | 573.0M |
| Gross Profit | 751.1M | 809.6M | 763.9M | 622.7M | 518.5M |
| Gross Margin % | 43.3% | 48.2% | 47.5% | 45.6% | 47.5% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 174.1M | - | 152.3M | 139.2M | 121.6M |
| Other Operating Expenses | 248.1M | 453.4M | 445.8M | 190.4M | 155.7M |
| Total Operating Expenses | 422.2M | 453.4M | 598.1M | 329.6M | 277.3M |
| Operating Income | 103.1M | 142.9M | 109.6M | 116.6M | 76.5M |
| Operating Margin % | 6.0% | 8.5% | 6.8% | 8.5% | 7.0% |
| Non-Operating Items | |||||
| Interest Income | 18.4M | - | 4.7M | 1.9M | 1.8M |
| Interest Expense | 741.0K | 5.4M | 6.4M | 5.0M | 12.0M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 111.1M | 151.3M | 109.2M | 88.8M | 30.9M |
| Income Tax | 30.4M | 39.8M | 30.6M | 26.2M | 8.2M |
| Effective Tax Rate % | 27.3% | 26.3% | 28.0% | 29.5% | 26.7% |
| Net Income | 80.8M | 111.6M | 78.6M | 62.6M | 22.6M |
| Net Margin % | 4.7% | 6.6% | 4.9% | 4.6% | 2.1% |
| Key Metrics | |||||
| EBITDA | 190.2M | 226.2M | 193.7M | 173.4M | 134.1M |
| EPS (Basic) | ₹5.82 | ₹8.04 | ₹5.66 | ₹4.51 | ₹1.63 |
| EPS (Diluted) | ₹5.82 | ₹8.04 | ₹5.66 | ₹4.51 | ₹1.63 |
| Basic Shares Outstanding | 13876668 | 13875373 | 13886572 | 13876668 | 13876668 |
| Diluted Shares Outstanding | 13876668 | 13875373 | 13886572 | 13876668 | 13876668 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Denis Chem Lab Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 8.5M | 11.9M | 24.8M | 13.0M | 15.7M |
| Short-term Investments | 250.6M | 246.0M | 144.0M | 65.8M | 11.3M |
| Accounts Receivable | 306.1M | 316.6M | 312.4M | 318.4M | 328.8M |
| Inventory | 98.1M | 101.9M | 91.2M | 98.9M | 91.1M |
| Other Current Assets | 214.0K | 17.3M | 263.0K | 20.7M | 13.2M |
| Total Current Assets | 706.4M | 693.7M | 592.4M | 533.2M | 485.5M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 39.9M | 374.4M | 37.9M | 37.7M | 37.7M |
| Goodwill | 1.1M | 1.8M | 2.2M | 2.8M | 1.4M |
| Intangible Assets | 1.1M | 1.8M | 2.2M | 2.8M | 1.4M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 3.9M | 6.8M | 10.0M | - | 5.3M |
| Total Non-Current Assets | 416.3M | 399.8M | 402.1M | 430.7M | 437.1M |
| Total Assets | 1.1B | 1.1B | 994.5M | 963.9M | 922.6M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 212.4M | 214.1M | 182.8M | 197.0M | 156.7M |
| Short-term Debt | 3.7M | 5.9M | 10.1M | 10.4M | 51.2M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 3.0M | 4.0M | 2.1M | 2.8M | 1.3M |
| Total Current Liabilities | 261.7M | 272.0M | 240.8M | 253.1M | 251.0M |
| Non-Current Liabilities | |||||
| Long-term Debt | 4.5M | 4.5M | 9.2M | 21.8M | 35.0M |
| Deferred Tax Liabilities | 1.1M | 9.6M | 19.4M | 18.6M | 8.3M |
| Other Non-Current Liabilities | -1.0K | - | - | -1.0K | 2 |
| Total Non-Current Liabilities | 10.0M | 17.9M | 31.1M | 46.3M | 56.6M |
| Total Liabilities | 271.7M | 289.8M | 271.8M | 299.4M | 307.6M |
| Equity | |||||
| Common Stock | 138.8M | 138.8M | 138.8M | 138.8M | 138.8M |
| Retained Earnings | 390.3M | - | 261.9M | 203.8M | 154.3M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 851.0M | 803.7M | 722.6M | 664.5M | 615.0M |
| Key Metrics | |||||
| Total Debt | 8.2M | 10.5M | 19.3M | 32.2M | 86.2M |
| Working Capital | 444.7M | 421.8M | 351.6M | 280.1M | 234.6M |
Balance Sheet Composition
Denis Chem Lab Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 111.1M | 151.3M | 109.2M | 88.8M | 30.9M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | 7.2M | -27.6M | 19.6M | 1.1M | 10.3M |
| Operating Cash Flow | 105.0M | 116.4M | 130.6M | 95.6M | 54.9M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | - | - | -69.2M | 1.1M | 1.0M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -34.7M | -27.8M | -20.8M | -10.4M | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | -12.8M | -54.0M | -39.5M |
| Financing Cash Flow | -37.0M | -31.9M | -33.9M | -105.2M | -76.0M |
| Free Cash Flow | 44.6M | 106.8M | 116.4M | 115.8M | 61.3M |
| Net Change in Cash | 68.0M | 84.4M | 27.4M | -8.5M | -20.1M |
Cash Flow Trend
Denis Chem Lab Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
12.26
Price to Book
1.22
Price to Sales
0.62
PEG Ratio
0.14
Profitability Ratios
Profit Margin
43.34%
Operating Margin
6.45%
Return on Equity
9.49%
Return on Assets
7.19%
Financial Health
Current Ratio
2.37
Debt to Equity
0.09
Per Share Data
EPS (TTM)
₹6.28
Book Value per Share
₹63.14
Revenue per Share
₹124.88
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| DENISCHEM | 1.1B | 12.26 | 1.22 | 9.49% | 43.34% | 0.09 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





